Mounjaro vs Trulicity: Which GLP-1 Works Better for Women?

What Is the Core Difference Between Mounjaro and Trulicity?

Mounjaro acts on two hormone receptors, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), while Trulicity activates GLP-1 receptors only. That dual mechanism is why tirzepatide consistently outperforms dulaglutide on both glucose control and body weight across every major trial. If weight loss is a central goal alongside blood sugar management, that difference matters a great deal.

Both drugs are once-weekly injectables approved by the FDA for type 2 diabetes. Mounjaro received its diabetes approval in May 2022, and its sister formulation Zepbound (same molecule, tirzepatide) received FDA approval for chronic weight management in November 2023. Trulicity has been on the market since 2014 and carries the strongest cardiovascular outcomes data of the two drugs right now.

How the Dual Mechanism Changes the Physiology

GLP-1 receptor agonists slow gastric emptying, suppress appetite through brain signaling, and stimulate glucose-dependent insulin release. Adding GIP receptor activation appears to amplify the weight-loss signal, possibly because GIP receptors in fat tissue and the central nervous system respond to the combination differently than to GLP-1 alone.

For women specifically, this matters because adipose tissue distribution, insulin sensitivity, and appetite regulation all shift with estrogen. Women in perimenopause and post-menopause experience a redistribution of fat toward visceral depots, and visceral fat is more metabolically active and more responsive to GLP-1-class drugs than subcutaneous fat.

Dosing Schedules Side by Side

Trulicity starts at 0.75 mg once weekly and can be titrated to 4.5 mg once weekly. Mounjaro starts at 2.5 mg once weekly and titrates through 5 mg, 7.5 mg, 10 mg, 12.5 mg, up to 15 mg once weekly. Both use an auto-injector pen. Side-effect intensity generally tracks the dose escalation speed, so slower titration reduces nausea in most people.

SURPASS-2 and REWIND: What the Trial Evidence Actually Shows

No published randomized controlled trial has put tirzepatide and dulaglutide head-to-head in the same study. What exists are separate phase 3 programs against different comparators, and cross-trial comparisons always carry important caveats about population differences, background therapies, and follow-up duration.

SURPASS-2: Tirzepatide vs Semaglutide, Not vs Dulaglutide

The SURPASS-2 trial (NEJM, 2021) randomized 1,879 adults with type 2 diabetes to tirzepatide 5 mg, 10 mg, or 15 mg versus semaglutide 1 mg weekly for 40 weeks. All three tirzepatide doses produced superior A1C reductions: 2.01%, 2.24%, and 2.58% respectively, compared with 1.86% for semaglutide 1 mg. Weight loss at 15 mg tirzepatide reached a mean of 11.2 kg (24.7 lb) versus 5.7 kg (12.6 lb) for semaglutide. Nausea, vomiting, and diarrhea occurred in roughly comparable proportions across groups.

Because SURPASS-2 tested tirzepatide against semaglutide, not dulaglutide, it does not give you a clean direct comparison to Trulicity. However, semaglutide 1 mg is widely considered a more potent GLP-1 agonist than dulaglutide at licensed doses, so tirzepatide's advantage over semaglutide implies an even larger gap versus dulaglutide.

REWIND: Dulaglutide's Cardiovascular Credential

The REWIND trial (Lancet, 2019) enrolled 9,901 adults with type 2 diabetes and either prior cardiovascular events or at least two cardiovascular risk factors. Dulaglutide 1.5 mg weekly reduced the composite of major adverse cardiovascular events (MACE, meaning nonfatal MI, nonfatal stroke, or CV death) by 12% versus placebo over a median 5.4 years of follow-up. That MACE benefit held in women, who made up 46% of the REWIND population, and dulaglutide reduced stroke specifically in the female subgroup.

Tirzepatide does not yet have a published dedicated cardiovascular outcomes trial. The SURMOUNT-MMO trial is ongoing as of early 2025, which means clinicians who need proven MACE reduction today must rely on the existing GLP-1 outcome data, where dulaglutide has an edge for now.

What the SURPASS Program Shows About Women

The SURPASS trials enrolled women at rates between 40% and 55% depending on the specific sub-study, which is better representation than older diabetes trials but still not a women-only analysis. A pooled analysis of the SURPASS program reported that women on tirzepatide experienced slightly greater percentage body weight reduction than men at equivalent doses, likely reflecting baseline differences in fat mass distribution and estrogen status. Sex-stratified data for dulaglutide from REWIND showed a similar or slightly attenuated glycemic benefit in women compared to men, though the cardiovascular benefit was preserved.

How Hormonal Status Changes the Picture for Women

Reproductive Years and Menstrual Cycle Effects

Both drugs suppress appetite and slow gastric emptying, which can alter the absorption timing of oral contraceptives. ACOG advises that patients on GLP-1 receptor agonists who use oral contraceptives should be counseled about potential reduced absorption, particularly during the titration phase when gastric emptying changes are greatest. A barrier method or non-oral contraceptive (IUD, implant, patch, ring) eliminates this concern.

Some women notice changes in cycle regularity within the first two to three months on either drug. This is likely secondary to weight loss itself, not a direct hormonal effect of the drug.

PCOS: A Condition Where GLP-1 Class Drugs Have Real Relevance

Polycystic ovary syndrome affects roughly 8% to 13% of women of reproductive age and is characterized by insulin resistance, hyperandrogenism, and ovulatory dysfunction. GLP-1 receptor agonists improve insulin sensitivity independently of weight loss, which can reduce androgen levels and restore ovulation.

Dulaglutide has been studied in small trials in women with PCOS, showing improvements in testosterone levels and menstrual regularity. Tirzepatide data in PCOS is emerging; the dual GIP and GLP-1 mechanism may offer additional benefit given GIP's role in adipose tissue signaling, but direct evidence specific to PCOS is limited as of 2025. If you have PCOS and are also trying to conceive, stop either drug before attempting pregnancy (see the pregnancy section below).

Perimenopause and Post-Menopause: The Weight Redistribution Problem

Falling estrogen levels during perimenopause shift fat storage from subcutaneous to visceral depots and lower resting metabolic rate. This makes weight loss harder and increases cardiometabolic risk. Both drugs can help, but tirzepatide's greater weight loss magnitude makes it more likely to produce clinically meaningful visceral fat reduction in this group.

A practical decision framework for menopausal women: if cardiovascular risk is the primary driver and proven MACE reduction is the goal, dulaglutide has that evidence today. If weight loss magnitude and glycemic control are the primary goals, tirzepatide's trial data is substantially stronger. Women on menopausal hormone therapy (MHT) can use either drug; there are no known pharmacokinetic interactions between estradiol-based MHT formulations and GLP-1 class agents.

Thyroid Considerations

Both drugs carry an FDA black box warning about the risk of thyroid C-cell tumors observed in rodent studies. Dulaglutide's prescribing label explicitly contraindicates the drug in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). The same contraindication applies to tirzepatide. Hashimoto's thyroiditis and hypothyroidism are common in women with PCOS and in perimenopausal women; neither condition is a contraindication to either drug, but levothyroxine absorption can be affected by delayed gastric emptying, so your dose may need rechecking after starting a GLP-1 class agent.

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

Both Mounjaro and Trulicity are contraindicated in pregnancy. This is not a relative caution. Stop either drug at least two months before attempting conception. Eli Lilly's animal reproduction studies for tirzepatide showed fetal harm at doses producing exposures similar to the maximum human dose. Dulaglutide animal studies showed reduced fetal growth and skeletal malformations.

Human data for both drugs in pregnancy is limited to case reports and registry observations; no controlled trial data exists, and none is ethically feasible. The FDA pregnancy category system has been replaced, but both drugs carry language in their labels specifying that they should be discontinued when pregnancy is detected and that women of childbearing potential should use effective contraception.

Lactation

Neither tirzepatide nor dulaglutide has been studied in human lactation. Animal data suggests both drugs are present in milk, but bioavailability via breastfeeding is expected to be low given they are large peptide molecules subject to gastrointestinal degradation. LactMed lists both GLP-1 receptor agonists as drugs where the risk to a breastfed infant is not established, and the Infant Risk Center recommends avoiding them during breastfeeding until more data is available. For most postpartum women, the practical guidance is to wait until breastfeeding is complete before restarting.

Contraception Requirements

If you are of reproductive age and on either drug:

• Use a non-oral contraceptive method during dose titration if possible (IUD, implant, injectable, ring, or patch).
• If you rely on oral contraceptives, take them at least one hour before your GLP-1 injection day or consider switching to a non-oral method.
• Plan to stop either drug at least eight weeks before attempting conception, to allow clearance and to ensure the fetal period is not exposed.
• Women with PCOS who restore ovulation on these drugs should not assume they remain anovulatory; unplanned pregnancy risk increases as cycles regularize.

Who This Is Right For, by Life Stage and Condition

Mounjaro (Tirzepatide) Is Likely the Better Choice If:

• You have type 2 diabetes and need both significant A1C reduction and meaningful weight loss.
• You are in perimenopause or post-menopause and visceral fat accumulation is your primary metabolic concern.
• You have obesity with type 2 diabetes and a BMI above 30 (or above 27 with a weight-related condition), and Zepbound is accessible to you as the weight-management approval.
• You have PCOS with significant insulin resistance and have not responded adequately to metformin.

Trulicity (Dulaglutide) Is Likely the Better Choice If:

• Proven cardiovascular outcome data matters most to you right now and you cannot wait for SURMOUNT-MMO results.
• You had a prior MACE event or have high cardiovascular risk and your cardiologist or endocrinologist wants a drug with REWIND-level evidence.
• Cost or insurance access is the deciding factor; dulaglutide has broader coverage in some formularies.
• Tolerability on a lower-efficacy drug is preferred while you assess your response to the class.

Neither Drug Is Right If:

• You are pregnant, planning pregnancy within two months, or breastfeeding.
• You have a personal or family history of MTC or MEN 2.
• You have a history of pancreatitis (use with caution for both; discuss with your clinician).
• You have severe gastroparesis, as both drugs slow gastric motility.

Side Effects: How They Differ and What Women Often Experience

Gastrointestinal side effects dominate both drug profiles. Nausea, vomiting, diarrhea, and constipation are the most common, peaking during dose escalation and generally improving after four to eight weeks at a stable dose.

GI Side Effect Rates Compared

In SURPASS-2, nausea occurred in 17% to 22% of tirzepatide patients depending on dose, and in 18% of semaglutide patients. In REWIND, nausea occurred in 13% of dulaglutide patients versus 9% on placebo. The side-effect profiles of tirzepatide and dulaglutide have not been compared in the same trial, but the GI burden with tirzepatide at higher doses appears somewhat greater, which is consistent with its greater weight-loss effect.

Women tend to report GI symptoms more intensely than men on GLP-1 agents, possibly because of baseline differences in gastric motility and estrogen's effects on gut smooth muscle. This is not a reason to avoid these drugs, but it is a reason to titrate slowly and not rush to the maximum dose.

Hair Loss

Telogen effluvium, the shedding of hair that follows rapid caloric restriction, is reported by a subset of women on both drugs. It is not a direct drug effect; it is a response to rapid weight loss. It typically begins two to four months after significant weight reduction and resolves within six months in most cases without treatment. A brief note in clinical guidance from AACE recommends monitoring for telogen effluvium in women on GLP-1 agents who lose more than 10% of body weight rapidly.

Muscle Mass

Rapid weight loss with any GLP-1 agent carries the risk of muscle mass loss alongside fat. Women already lose muscle mass accelerating after age 40, so adequate protein intake (at least 1.2 g per kg of body weight) and resistance training should be co-prescribed with either drug for women in the perimenopausal and post-menopausal years.

Switching Between Drugs: What the Evidence Says

Can you switch from Trulicity to Mounjaro, or vice versa? Clinically, yes. No washout period is typically required when switching between GLP-1 class agents or from a GLP-1 agent to a dual GIP/GLP-1 agent because the drugs compete for the same receptor (and tirzepatide adds the GIP receptor on top).

The ADA Standards of Medical Care in Diabetes recommend that intensification of glucose-lowering therapy should consider cardiometabolic risk, weight goals, tolerability, and cost. Switching from dulaglutide to tirzepatide is a reasonable intensification strategy if glycemic or weight targets have not been met. Starting tirzepatide at the lowest dose (2.5 mg weekly) when switching is generally recommended to allow GI acclimatization to the new agent.

Switching from Mounjaro back to Trulicity is less common clinically but might occur due to cost, formulary changes, cardiovascular outcome preference, or side-effect burden. When switching down in potency, expect some weight regain.

Cost, Access, and the Real-World Decision

Tirzepatide is substantially more expensive without insurance coverage. The list price for Mounjaro or Zepbound without a coupon or insurance can reach $1,000 per month or more. Trulicity's list price is similarly high, though it has been on the market longer and biosimilar competition may alter this in coming years.

For women navigating employer insurance, Mounjaro tends to have better coverage when the diagnosis is type 2 diabetes, while Zepbound (tirzepatide for weight management) faces more frequent prior authorization rejections when prescribed without a diabetes diagnosis. Women with PCOS who are prescribed these drugs off-label for insulin resistance and weight management face the most variable coverage field.

Manufacturer savings programs exist for both drugs for commercially insured patients, but they do not apply to Medicare or Medicaid beneficiaries. This is a real equity issue for older women or those in lower-income brackets.

The Evidence Gap: What We Do Not Yet Know

Women have been underrepresented in metabolic drug trials for decades, and the GLP-1 program is only partially better. Sex-stratified sub-analyses of SURPASS-2 and REWIND exist, but they were not powered to detect sex-specific differences in primary outcomes. We do not have:

• A dedicated tirzepatide trial in women with PCOS.
• Long-term data on tirzepatide's effect on bone density in post-menopausal women.
• Pharmacokinetic data on either drug across the menstrual cycle.
• Lactation transfer data in humans for either drug.
• Cardiovascular outcomes data for tirzepatide from a completed large trial.

What is extrapolated from men to women: the cardiovascular mechanism of GLP-1-mediated MACE reduction. What is directly studied in women: the REWIND female subgroup showing preserved stroke reduction with dulaglutide, and the SURPASS pooled sex-stratified weight analysis. Honest clinicians will tell you that, for some of these questions, we are working with the best available evidence rather than definitive answers.